WO2023110833 - PHARMACEUTICAL FORMULATIONS COMPRISING A CYCLODEXTRIN
National phase entry:
Publication Number
WO/2023/110833
Publication Date
22.06.2023
International Application No.
PCT/EP2022/085558
International Filing Date
13.12.2022
Title **
[English]
PHARMACEUTICAL FORMULATIONS COMPRISING A CYCLODEXTRIN
[French]
FORMULATIONS PHARMACEUTIQUES COMPRENANT UNE CYCLODEXTRINE
Applicants **
NOVO NORDISK A/S
Inventors
KJELDSEN, Benjamin, Troest
CHRISTOFFERSEN, Stig
HANSEN, Rosa, Rebecca, Erritzøe
Priority Data
21214004.0
13.12.2021
EP
22191564.8
22.08.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2510 | |
| EPO | Filing, Examination, Granting | 9794 | |
| Japan | Filing, Examination, Granting | 2171 | |
| South Korea | Filing, Examination, Granting | 2076 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,291
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein is a liquid pharmaceutical formulation comprising an amylin receptor agonist, a GLP-1 receptor agonist and a cyclodextrin comprising hydroxypropyl substitutions. Said co-formulation may be used for the medical treatment of subjects with overweight or obesity, with or without associated co-morbidities; diabetes, with or without associated comorbidities; cardiovascular diseases, non-alcoholic steatohepatitis (NASH) and cognitive impairment, such as that caused by Alzheimer's disease.[French]
L'invention concerne une formulation pharmaceutique liquide comprenant un agoniste du récepteur de l'amyline, un agoniste du récepteur du GLP-1 et une cyclodextrine comprenant des substitutions d'hydroxypropyle. Ladite coformulation peut être utilisée pour le traitement médical de sujets atteints de surpoids ou d'obésité, avec ou sans comorbidités associées ; de diabète, avec ou sans comorbidités associées ; de maladies cardiovasculaires, de la stéatohépatite non alcoolique (NASH) et d'une déficience cognitive, telle que celle causée par la maladie d'Alzheimer.